GlaxoSmithKline, the UK based pharmaceutical group, plans to reduce the prices of many of its leading medicines in emerging markets , following the success of a pilot programme in the Philippines.

Andrew Witty, chief executive, told the Financial Times that he would cut prices to boost sales volumes across the world’s emerging markets as part of his strategy to create a more global and diversified business.